Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Somnomed Limited (SOM) Share Price & Analysis

7 Followers

SOM Stock Chart & Stats

A$0.29A$0.01(0.00%)
At close: 4:00 PM GMT+11
AU$0.25AU$0.3AU$0.35AU$0.4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
AUD 0.29 - AUD 0.29
52-Week Range
AUD 0.23 - AUD 0.81
Previous Close
AUD 0.29
Volume
N/A
Average Volume (3M)
53.72K
Market Cap
AUD 63.73M
Enterprise Value
AUD 102.25M
Total Cash (Recent Filing)
AUD 17.18M
Total Debt (Recent Filing)
AUD 5.46M
Price to Earnings (P/E)
―
Beta
1.22
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

EBITDA Growth And Margin Expansion

Improving EBITDA and margins indicate that SomnoMed is converting revenue into operating earnings more effectively through better gross margin and cost discipline. If maintained, this strengthens internal funding capacity and provides a more durable platform for investment in products, capacity, and international growth.

Conservative Balance Sheet

The substantial reduction in leverage lowers financial risk and gives SomnoMed greater flexibility to manage operating volatility or fund strategic initiatives. A capital base supported by meaningful equity also reduces dependence on borrowing while the company works to restore consistently positive shareholder returns.

Strengthened Cash Generation

Positive operating and free cash flow in the latest two years is an important improvement from earlier cash-flow volatility. Continued cash conversion would support product development, manufacturing investment, and balance-sheet resilience without relying as heavily on external capital.

Bears Say

Net Losses And Negative Returns

Despite improved operating profitability, SomnoMed remains loss-making after items below EBIT and is not yet generating positive returns on shareholder capital. This limits the quality and durability of earnings, leaving further dependence on operational improvement before growth can translate into stronger bottom-line returns.

Structural European Access Pressure

Europe is SomnoMed’s largest region, so structural changes to eligibility, reimbursement, and referrals can affect demand beyond a single reporting period. The resulting commercial and leadership restructuring suggests that restoring regional growth may require sustained execution and adaptation rather than a temporary sales recovery.

Competitive Market Pressure

A broader set of treatment options and lower-cost alternatives could make clinical differentiation and adoption more difficult over time. These competitive shifts may pressure SomnoMed’s ability to defend market share and sustain growth unless its oral appliances demonstrate clear advantages across clinician and patient adoption pathways.

Somnomed Limited News

SOM FAQ

What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.23 and its highest was AU$0.81 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$63.73M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Somnomed Limited released its earnings results on Aug 27, 2026. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of AU$0.004 by -AU$0.014.
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,768,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Somnomed Limited reported an EPS of -AU$0.01 in its last earnings report, missing expectations of AU$0.004. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology